StemoniX Inc. announced the appointment of Andrew (Andy) D. C. LaFrence, CPA, as Chief Financial Officer (CFO). Mr. LaFrence brings 35 years of accounting, finance, and operations experience to StemoniX, including executive management positions at public and private life sciences companies. As CFO, Mr. LaFrence will be responsible for leading StemoniX's finance and capital markets activities, as well as implementing initiatives to support the growth and market penetration of the company's microOrgan technology platforms. Prior to joining StemoniX, Mr. LaFrence served as Senior Vice President and CFO of Biothera Pharmaceuticals Inc. from May 2018 to July 2019.